International Journal of Hepatology最新文献

{"title":"Safety and Drug-Drug Interaction Burden of Direct-Acting Antiviral Therapy for Hepatitis C: A Single-Center Community Hospital Analysis.","authors":"Satoru Okabe, Akira Doi, Kengo Matsumoto, Masashi Yamamoto, Koji Fukui, Tsutomu Nishida","doi":"10.1155/ijh/5499912","DOIUrl":"https://doi.org/10.1155/ijh/5499912","url":null,"abstract":"<p><strong>Background: </strong>Polypharmacy leads to drug-drug interactions (DDIs) with direct-acting antivirals (DAAs). We quantified the DDI burden (Liverpool categories) and evaluated its association with effectiveness and safety. We assessed renal function as a predictor of adverse events (AEs) and reported loss to follow-up (LTFU).</p><p><strong>Methods: </strong>We retrospectively analyzed 145 adults with chronic hepatitis C treated with glecaprevir/pibrentasvir (GLE/PIB) or sofosbuvir/velpatasvir (SOF/VEL) between February 2018 and October 2024. The primary endpoint was sustained virological response 12 weeks after the end of treatment (SVR12); when SVR12 was missing, SVR24 was substituted (hierarchical SVR). Concomitant drugs were screened using the Liverpool HEP Drug Interaction Checker. The predictors of AEs were assessed using multivariable logistic regression and receiver operating characteristic analysis. A conservative intention-to-treat analysis included missing SVR data as a failure.</p><p><strong>Results: </strong>The median patient age was 67 years, and 23.4% of patients had cirrhosis. Polypharmacy (≥ 5 drugs) occurred in 26.9% of patients, DDIs in 50.3%, multiple DDIs in 14.5%, and contraindicated pairs in 1.4% (all GLE/PIB). AEs occurred in 16.6% of patients, were largely Grades 1-2, and began around Week 2. LTFU was 11.0%. The hierarchical SVR was 99.2%, whereas the conservative analysis was 88.3%. A Cr concentration ≥ 0.86 mg/dL independently predicted AEs (adjusted OR 3.4; 95% CI 1.24-9.2), whereas DDI burden and polypharmacy did not.</p><p><strong>Conclusions: </strong>Despite frequent DDIs, DDI burden was not independently associated with SVR or AEs. DAA therapy was highly effective and well tolerated. Renal function showed a modest association with AEs.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2026 ","pages":"5499912"},"PeriodicalIF":1.4,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13136848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing Landscape of Chronic Liver Diseases in a Tertiary Level Hospital of Bangladesh Over the Last 10 Years.","authors":"Md Hasan Shahriar, Avizit Sarker, Tapu Ghosh, Md Enamol Hoque, Md Samsul Arafin, Md Tanveer Rahman, Md Shahinul Alam","doi":"10.1155/ijh/5525981","DOIUrl":"https://doi.org/10.1155/ijh/5525981","url":null,"abstract":"<p><p>Given significant advances in the treatment of viral hepatitis and the growing epidemic of obesity, the burden of the different types of chronic liver diseases in Bangladesh may be changing. Our aim was to assess the shift in the prevalence of different chronic liver disease etiologies in a tertiary level hospital of Bangladesh over the last 10 years. This was a retrospective observational study conducted in the Department of Hepatology in Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. It was based on data from the hospital records (2013-2016 and 2017-2022). A total of 4658 patients were included from the hospital registry between 2013 and 2022. The etiologies of chronic liver disease were compared between two time periods: (2013-2016) and (2017-2022) among these patients. A significant decrease in the prevalence of chronic hepatitis B from 51.1% (2013-2016) to 44.4% (2017-2022) (<i>p</i> < 0.001), chronic hepatitis C from 11.3% (2013-2016) to 10.4% (2017-2022) (<i>p</i> = 0.032), and non-B-non-C from 11.7% (2013-2016) to 8.6% (2017-2022) (<i>p</i> < 0.001) was observed. In contrast, the prevalence of nonalcoholic fatty liver disease (NAFLD/NASH) increased from 1.2% (2013-2016) to 8.1% (2017-2022) (<i>p</i> < 0.001); anti-HBc (total) from 3.2% (2013-2016) to 5.1% (2017-2022) (<i>p</i> = 0.001), and autoimmune hepatitis (AIH) from 0.2% (2013-2016) to 0.4% (2017-2022) (<i>p</i> = 0.038) also showed a significant increase. Over the last decade (2013-2022), NAFLD has emerged as a rapidly increasing cause of chronic liver disease in Bangladesh, whereas viral etiologies and AIH show a declining trend. Policy makers, clinicians, and stakeholders should take attention to recognize the situation and act properly.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2026 ","pages":"5525981"},"PeriodicalIF":1.4,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13125336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147822189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natriuretic Effect of Dapagliflozin in Cirrhosis With Ascites: A Randomized, Placebo-Controlled Crossover Trial.","authors":"Nattaporn Kongphakdee, Setthachai Piewchan, Kanokporn Sanpawithayakul, Soonthorn Chonprasertsuk, Sith Siramolpiwat","doi":"10.1155/ijh/9503323","DOIUrl":"https://doi.org/10.1155/ijh/9503323","url":null,"abstract":"<p><strong>Background: </strong>Ascites is a frequent complication of decompensated liver cirrhosis and is associated with a poor prognosis. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, induces osmotic diuresis and natriuresis, with established use in heart failure. However, studies on SGLT2 inhibitors in cirrhotic patients with ascites are limited.</p><p><strong>Objectives: </strong>The objective of this study is to evaluate changes in urine parameters in cirrhotic patients with ascites treated with dapagliflozin.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled, crossover trial enrolled 10 patients with Child-Pugh Class B or C cirrhosis who had persistently moderate or tense ascites. Participants received dapagliflozin or placebo for 4 weeks, followed by a 2-week washout, and then crossed over to alternate treatment. The primary outcome was the change in 24-h urine sodium (UNa) excretion on Days 0, 3, and 28. Secondary outcomes included changes in 24-h urine volume (UV) and serum sodium.</p><p><strong>Results: </strong>Dapagliflozin significantly increased 24-h urinary sodium excretion at Day 3 compared with placebo (treatment difference +35.1 mmol/day; 95% CI 17.5-52.7; <i>p</i> < 0.001), indicating a transient natriuretic effect. This effect was not sustained at Day 28 (<i>p</i> = 0.42). There were no significant changes in 24-h UV or serum sodium at either time point. At the end of the dapagliflozin phase, 5 of 7 evaluable participants demonstrated improvement in ascites grade, whereas 2 did not. One serious adverse event occurred; one participant died during the washout period after completing the placebo phase due to variceal bleeding complicated by spontaneous bacterial peritonitis.</p><p><strong>Conclusions: </strong>In cirrhotic patients with persistent ascites, dapagliflozin was associated with a transient increase in 24-h urinary sodium excretion, without significant sustained effects on urine volume or serum sodium. Dapagliflozin was generally well tolerated in this small pilot trial.</p><p><strong>Trial registration: </strong>Thai Clinical Trial Registry: TCTR20241016007.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2026 ","pages":"9503323"},"PeriodicalIF":1.4,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13058925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147647042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Liver Enzymes and Metabolic Syndrome: A Population-Based Cross-Sectional Study of the Bandar Kong Cohort Study.","authors":"Arezoo Ghazalgoo, Masoumeh Kheirandish, Seyyed Mohammad Hashemi, Elaheh Salarpour, Ayoub Basham, Parsa Saberian, Ehsan Amini-Salehi, Hoda Safa","doi":"10.1155/ijh/8920064","DOIUrl":"https://doi.org/10.1155/ijh/8920064","url":null,"abstract":"<p><strong>Background: </strong>Metabolic syndrome (MetS) is a major global health concern that increases morbidity and mortality from cardiometabolic diseases. We refined the rationale to highlight the mechanistic involvement of the liver in metabolic dysregulation.</p><p><strong>Methods: </strong>This population-based study was conducted on 3896 adults aged between 35 and 70 (57.2% female) who participated in the Bandare-Kong Non-Communicable Diseases (BKNCD) cohort study. Participants were categorized into normal quartiles and abnormal levels of liver enzymes including gamma-glutamyl transferase (GGT), alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP). MetS was defined based on the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for Iranian population. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) and <i>p</i> values, adjusting for age, sex, residence, BMI, physical activity, energy intake, and financial status.</p><p><strong>Results: </strong>The prevalence of MetS was 36.6%. After multivariable adjustment, abnormal levels of GGT (OR = 1.91, 95% CI: 1.61-2.28, <i>p</i> < 0.001), ALT (OR = 1.60, 95% CI: 1.34-1.90, <i>p</i> < 0.001), ALP (OR = 1.48, 95% CI: 1.07-2.03, <i>p</i> = 0.01), and AST (OR = 1.39, 95% CI: 1.09-1.77, <i>p</i> = 0.007) were significantly associated with higher odds of MetS. Within normal ranges, the highest quartile of GGT (OR = 2.81, 95% CI: 2.22-3.56, <i>p</i> < 0.001), ALT (OR = 2.39, 95% CI: 1.89-3.03, <i>p</i> < 0.001), and ALP (OR = 1.63, 95% CI: 1.30-2.04, <i>p</i> < 0.001) showed significant associations, while AST did not.</p><p><strong>Conclusion: </strong>Serum liver enzyme levels, including those within normal range, were strongly associated with MetS. GGT showed relatively stronger associations compared with other enzymes; however, these findings should not be interpreted as diagnostic superiority because no performance metrics (AUC, PPV, and NPV) were evaluated. ALT and ALP also showed meaningful associations. Future studies should assess diagnostic accuracy before considering clinical implementation.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2026 ","pages":"8920064"},"PeriodicalIF":1.4,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13059668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147646983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Learning Models to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With Simple Anthropometric and Biochemical Variables: A Cross-Sectional Study in US Population.","authors":"Shiying Du, Hailiang Yu, Jianbo Du, Yunan Xu","doi":"10.1155/ijh/8221645","DOIUrl":"https://doi.org/10.1155/ijh/8221645","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global health concern. This study was aimed at exploring the feasibility of utilizing machine learning (ML) algorithms to predict MASLD in large general populations based on simple anthropometric and biochemical parameters.</p><p><strong>Methods: </strong>Data from the 2017-2020 cycles of the US National Health and Nutrition Examination Survey (NHANES) were utilized. A total of 6814 participants (53.0% female) with complete transient elastography data were included. MASLD was defined as a controlled attenuation parameter ≥ 280 dB/m, with cardiometabolic risk factor and without excessive alcohol use. Key characteristics and biomarkers associated with MASLD were identified using the least absolute shrinkage and selection operator (LASSO) and the Boruta algorithms. ML methods, including logistic regression (LR), extreme gradient boosting (XGBoost), bootstrap aggregating, random forest, naive Bayes, light gradient boosting machine (LightGBM), decision tree, and support vector machines, were employed to develop the MASLD prediction models.</p><p><strong>Results: </strong>The median age of the 6814 participants was 53 years (interquartile range: 37~65). MASLD was detected among 2611 (38.3%) participants. Key predictors selected via LASSO and Boruta algorithms included body weight, standing height, waist circumference, diagnosis of diabetes, alanine aminotransferase, aspartate aminotransferase, and gamma glutamyl transferase. The areas under the receiver operating characteristic curves of LR, XGBoost, and other ML models were 0.841, 0.837, 0.815, 0.838, 0.814, 0.842, 0.796, and 0.828 in the internal validation cohort. Results indicate that LR, XGBoost, and LightGBM models outperform other models in predicting MASLD.</p><p><strong>Conclusions: </strong>The ML models of LR, XGBoost, and LightGBM are effective and simplified tools for predicting MASLD in the US general population. This study underscores the potential of ML models with simple noninvasive biomarkers in enhancing early detection and personalized management of fatty liver disease.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2026 ","pages":"8221645"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13042330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Bulevirtide, Interferons, and Nucleos(t)ide Analogs for Chronic Hepatitis Delta: A Systematic Review and Network Meta-Analysis.","authors":"Rohan Karkra, Mahinaz Mohsen, Joshua E Pagán-Busigó, Ethan Shamsian, Michael Bebawy, Steven Rella, Zaid Tafesh, Paul Gaglio","doi":"10.1155/ijh/6325996","DOIUrl":"https://doi.org/10.1155/ijh/6325996","url":null,"abstract":"<p><strong>Background: </strong>Chronic hepatitis D virus (HDV) continues to be a global health concern, and the infection remains challenging to treat. Over the past few decades, pegylated interferons, typically in combination with therapy for hepatitis B, have become the standard of care, with considerable side effects and frequently unsatisfactory results. Several new therapies are emerging, including bulevirtide and lonafarnib. We conducted a systematic review and network meta-analysis (NMA) to compare the efficacy of bulevirtide, interferons, and nucleos(t)ide analogs, alone or in combination, for the treatment of chronic hepatitis D.</p><p><strong>Methods: </strong>PubMed, Embase, and Cochrane databases were searched for randomized controlled trials and nonrandomized interventional studies assessing HDV RNA suppression, biochemical response, combined response, and histological improvement with various therapies. NMA was performed using a frequentist random-effects model. Odds ratios (OR) with 95% confidence intervals (CI) were calculated and forest plots were generated.</p><p><strong>Results: </strong>Thirteen studies (<i>n</i> = 922) were included, studying nine possible treatment arms. At the end of treatment, 31.8% achieved a virological response. Bulevirtide monotherapy (OR 38.63, <i>p</i> < 0.05) and combinations with NA (OR 69.36, <i>p</i> < 0.05) and peginterferon alpha (OR 260.08, <i>p</i> < 0.05) significantly suppressed HDV RNA, with the bulevirtide-peginterferon alpha combination having the highest HDV RNA suppression. At ≥ 24-week follow-up, no regimen maintained significant HDV RNA suppression. Biochemical response was achieved in 42.7% at the end of treatment; however, no group reached statistical significance versus control, though bulevirtide and its combination with peginterferon alpha outperformed peginterferon alpha alone. Combined response was highest with bulevirtide-peginterferon alpha (OR 112.69, <i>p</i> < 0.05), followed by bulevirtide monotherapy. Histological response (five studies, <i>n</i> = 183) was not statistically significant with any intervention compared with control.</p><p><strong>Conclusion: </strong>Bulevirtide and peginterferon alpha combination therapy may offer the most promising treatment for chronic hepatitis D. More studies are needed to assess the efficacy of this regimen and establish the optimum dose and duration of treatment.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2026 ","pages":"6325996"},"PeriodicalIF":1.4,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13122728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C.","authors":"Seiichi Tawara, Asuka Watanabe, Junya Yamaguchi, Mai Omi, Tetsuro Miyazaki, Haruka Taguchi, Ryosuke Kiyota, Takuo Yamai, Shoichiro Kawai, Takuya Inoue, Takayuki Yakushijin","doi":"10.1155/ijh/5053151","DOIUrl":"10.1155/ijh/5053151","url":null,"abstract":"<p><strong>Aim: </strong>The use of direct-acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later-generation DAAs, glecaprevir (GLE) and pibrentasvir (PIB), to investigate the clinical challenges associated with HCV treatment.</p><p><strong>Methods: </strong>A total of 141 consecutive patients who underwent GLE/PIB therapy for chronic HCV infection between December 2017 and June 2021 were enrolled. Patient backgrounds and adherence were retrospectively analyzed.</p><p><strong>Results: </strong>Median patient age was 61 years. Eighteen patients had a history of injecting drug use (IDU), accounting for 13% of the sample. At the end of treatment, three patients (2.1%) self-discontinued hospital visits. The number of patients who self-discontinued hospital visits gradually increased over time to 9 (6.4%) at 4 weeks after treatment, 16 (11.3%) at 12 weeks after treatment, and 24 (17.0%) at 24 weeks after treatment. The sustained viral response rate after 12 weeks, excluding patients who self-discontinued hospital visits, was 96.8% (121/125). In a multivariate analysis, age < 60 years and a history of IDU were significant factors associated with the self-discontinuation of hospital visits. The hazard ratio (HR) for those younger than 60 years old was 3.17 (<i>p</i> = 0.012), whereas the HR for those with a history of IDU was 2.41 (<i>p</i> = 0.036).</p><p><strong>Conclusions: </strong>History of IDU and younger age were significantly associated with poor adherence to GLE/PIB treatment.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2026 ","pages":"5053151"},"PeriodicalIF":1.4,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12820713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Bivariate Meta-Analysis of FIB-4 Cut-Offs to Rule Out Advanced Fibrosis in MASLD.","authors":"Anuradha Ghosal, Samit Ghosal","doi":"10.1155/ijh/9419416","DOIUrl":"10.1155/ijh/9419416","url":null,"abstract":"<p><strong>Background: </strong>The fibrosis-4 (FIB-4) index, a non-invasive marker, evaluates advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), but the variability in its performance across different populations remains unclear.</p><p><strong>Methods: </strong>We conducted a systematic review and bivariate meta-analysis of 14 studies (<i>N</i> = 5521) with 2 × 2 contingency data for FIB-4 at thresholds < 1.0 and < 1.3, compared with liver biopsy or transient elastography (TE). The Reitsma model (R v4.4.3) estimated pooled sensitivity and specificity. Subgroup analyses assessed region (India vs. global) and reference standard effects, with heterogeneity and publication bias (Deeks' test) evaluated.</p><p><strong>Results: </strong>Pooled sensitivity was 0.73 (95% CI: 0.69-0.77), and specificity was 0.69 (95% CI: 0.61-0.76) at < 1.3. The < 1.0 threshold demonstrated higher specificity (0.83, 95% CI: 0.75-0.89) but lower sensitivity (0.63, 95% CI: 0.58-0.68). Indian cohorts (<i>n</i> = 3) exhibited higher specificity (0.83) than the global estimate (0.66) at < 1.3, whereas sensitivity remained similar.</p><p><strong>Conclusion: </strong>FIB-4 below 1.3 is a useful initial tool for ruling out advanced fibrosis in MASLD, with potential regional variations in specificity. Larger studies are needed to confirm cut-offs, supporting tailored guidelines with sequential testing.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2026 ","pages":"9419416"},"PeriodicalIF":1.4,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12801200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noninvasive Assessment of Prehepatic Portal Hypertension: Pilot Data on Spleen Stiffness in Portal Vein Thrombosis.","authors":"Kelly Tin Long Chan, Oi Ling Chan, Yin Yee Lam, Siu Wing Lawrence Lai","doi":"10.1155/ijh/5531253","DOIUrl":"10.1155/ijh/5531253","url":null,"abstract":"<p><strong>Background: </strong>Portal vein thrombosis (PVT) is a vascular liver disorder defined by a thrombus in the portal vein or its intrahepatic branches. Computed tomography (CT) and upper endoscopy are, respectively, used to monitor for PVT progression and portal hypertensive complications. A noninvasive modality-spleen stiffness (SS)-has shown promise in identifying clinically significant portal hypertension (CSPH) in cirrhosis. It is unknown whether SS demonstrates any correlation with PVT, a condition associated with prehepatic portal hypertension.</p><p><strong>Aims: </strong>The primary aim was to determine the association between SS and the presence of PVT. The secondary aim was to evaluate the association between SS and portal hypertension-related complications among patients with PVT.</p><p><strong>Methods: </strong>This cross-sectional study was undertaken at two regional hospitals in Hong Kong from January 2023 to March 2024. Patients were identified via CT and allocated to either the PVT or non-PVT group. Chronic liver disease was an exclusion criterion for both groups. SS was assessed using transient elastography within 3 months of PVT diagnosis. Demographic, clinical, and laboratory data were collected within 3 months of PVT diagnosis.</p><p><strong>Results: </strong>A total of 46 patients with PVT (median age, 69 years; interquartile range [IQR], 62-78; 74% male) were compared with 45 controls. Both SS and liver stiffness (LS) were significantly higher in the PVT cohort than in controls (SS: 27.9 [IQR, 19.5-42.8] vs. 16.9 kPa [IQR, 13.6-21.2], <i>p</i> < 0.001; LS: 6.0 [IQR, 4.8-8.6] vs. 4.6 kPa [IQR, 3.7-5.9], <i>p</i> < 0.001). Among patients with PVT, those with portal hypertension-related complications demonstrated markedly elevated SS compared with those without complications (77.7 [IQR, 47.2-85.0] vs. 24.4 kPa [IQR, 18.9-37.1], <i>p</i> < 0.001). Furthermore, SS values increased in proportion to the anatomical extent of PVT involvement.</p><p><strong>Conclusion: </strong>Elevated SS was observed in patients with PVT, particularly in those with PVT-induced portal hypertension. Large-scale, prospective studies are warranted to confirm the association between SS and PVT and to establish its potential role in noncirrhotic portal hypertension.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2025 ","pages":"5531253"},"PeriodicalIF":1.4,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12752816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145879254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PFKL Inhibition by DT-13: A Novel Approach to Combat Hepatocellular Carcinoma.","authors":"Qiang Yu, Liangning Hu, Chenfei Tan, Min Gao, Zhenzhen Wen","doi":"10.1155/ijh/5211859","DOIUrl":"10.1155/ijh/5211859","url":null,"abstract":"<p><p>Aerobic glycolysis modulates proliferation, apoptosis, immune evasion, and targeted drug resistance in hepatocellular carcinoma (HCC) patients. Therefore, inhibiting aerobic glycolysis could represent a novel chemotherapeutic strategy for HCC. The effects of <i>Liriope muscari</i> Baily's Saponin C (DT-13), a novel compound isolated from the traditional Chinese medicine <i>Liriope muscari</i> (Decne) Baily, on HCC and its underlying mechanism remain unknown. This study revealed that DT-13 induces apoptosis and inhibits the in vivo and in vitro proliferation of HCC cells. Furthermore, DT-13 significantly reduced glucose consumption and lactate production. Moreover, it was observed that DT-13 could inhibit Phosphofructokinase-1 liver (PFKL) type via c-myc signaling to modulate the aerobic glycolysis, proliferation, and apoptosis of HCC. Moreover, DT-13 improved the anticancer effects of sorafenib in HCC. In summary, this study provided evidence for the potential application of DT-13 in HCC treatment.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2025 ","pages":"5211859"},"PeriodicalIF":1.4,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12752837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145879260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}